In vitro activity of sulperazon against recent isolates of ceftazidime-resistant bacteria.
The in vitro activity of sulperazon (cefoperazone/sulbactam) was tested against 94 ceftazidime-resistant strains of bacteria isolated from mostly seriously ill patients in critical care units. Acinetobacter baumanii, Pseudomonas aeruginosa and Klebsiella pneumoniae made up 80% of the pathogens studied; 90% of the Klebsiella strains were producers of extended-spectrum beta-lactamases (ESBL). The MIC90 of sulperazon for Klebsiella was 12 mg/l (range 1.5-16 mg/l), indicating that this drug may be a useful alternative for the treatment of ceftazidime-resistant, ESBL-producing Klebsiella.
Lim
V K
VK
Infectious Diseases Research Centre, Institute of Medical Research, Kuala Lumpur.
Halijah
M Y
MY
D000150:Acinetobacter / Q000187:drug effects; D001419:Bacteria / Q000187:drug effects*; D002438:Cefoperazone / Q000494:pharmacology*; D002442:Ceftazidime / Q000494:pharmacology*; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D006801:Humans; D066298:In Vitro Techniques; D007711:Klebsiella pneumoniae / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013407:Sulbactam / Q000494:pharmacology*
D004338:Drug Combinations; D002438:Cefoperazone; C057923:sulperazone; D002442:Ceftazidime; D013407:Sulbactam